Skip to content

Hematological Disorders in Covid 19 Patients

Hematological Disorders in Covid 19 Patients

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05182528
Enrollment
200
Registered
2022-01-10
Start date
2022-01-31
Completion date
2023-04-30
Last updated
2022-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematological Abnormalities in covid19

Brief summary

aim of the research is to detect hematological abnormalities in covid 19 patients and its correlation with the severity and outcome of the disease.

Detailed description

Covid 19 is an infectious disease caused by a newly discovered coronavirus.most people infected with the covid 19 virus will have mild to moderate respiratory illness and recover without specific treatment.older people and those with underlying medical problems like cardiac diseases,diabetes,any chronic respiratory disease and cancer are more likely to have serious illness.the covid 19 virus spreads primarily through droplets of saliva or discharge from the nose oral cavity when an infected person coughs or sneezes.people with covid19 have had a wide range of symptoms reported \_ranging from mild to severe symptoms.symptoms may appear 2\_14 days after exposure to the infection .any one can have mild to severe symptoms.people with these symptoms may have covid 19: fever or shivering,cough,shortness of breath,fatigue,body or muscle aches,headache,new loss of smell or taste ,sore thraot,congestion or running nose , nausea or vomiting,diarrhoea. The most common hematological clinical findings include lymphocytopenia,neutrophilia,eosinophilia,mild thrombocytopenia,and less frequently thrombocytosis,the presence of reactive lymphocytes has been reported only occasionally the leucocyte count may be normal,reduced or increased.according to a meta analysis leucocytosis,lymphopenia and thrombocytopenia are associated with greater severity and fatality in covid 19 cases

Interventions

None listed

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years

Inclusion criteria

all covid 19 patients diagnosed by pcr or CT chest \-

Exclusion criteria

* No

Design outcomes

Primary

MeasureTime frameDescription
Hematological disorders in covid 19 patientsBaselineto detect hematological abnormalities in covid 19 patients and its correlation to outcome and severity of the disease

Contacts

Primary ContactRadwa mahmoud
Radwaamahmoud11@gmail.com01001673731
Backup Contactmohamed hossam maghraby
Mohamedmaghraby@yahoo.com01002621166

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026